Corporate Profile for Alza Corp., dated April 4, 1997.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: April 4, 1997
Company Name: Alza Corp.
Address: 950 Page Mill Road
P.O. Box 10950
Palo Alto, CA 94303-0802
Main Telephone
Number: 415/494-5000
Internet Home
Page Address
(URL) www.alza.com
Chief Executive
Officer: Ernest Mario, Ph.D.
Chief Financial
Officer: Bruce C. Cozadd
Investor Relations
Contact: Michael Boennighausen
Business number: 415/494-5222
Public Relations
Contact: Anneke L. Cole
Business number: 415/494-5222
Trading Symbol
Exchange: NYSE: AZA
Industry: Healthcare/Pharmaceuticals
Company description: ALZA Corporation is a leader in the development and commercialization of innovative pharmaceutical products using advanced drug delivery technologies to add medical and economic value to drug therapies. Products developed by ALZA include Procardia XL (nifedipine nifedipine /ni·fed·i·pine/ (ni-fed´i-pen) a calcium channel blocking agent used as a coronary vasodilator in the treatment of coronary insufficiency and angina pectoris; also used in the treatment of hypertension. ), the largest-selling cardiovascular product for the treatment of angina and hypertension in the United States. Transderm-Nitro (nitroglycerin nitroglycerin (nī'trōglĭs`ərĭn), C3H5N3O9, colorless, oily, highly explosive liquid. It is the nitric acid triester of glycerol and is more correctly called glycerol trinitrate. ) for the treatment of angina pectoris, Duragesic (fentanyl transdermal system fentanyl transdermal system Warning - High-alert drug! Duragesic, Durogesic (UK), Tilofyl Pharmacologic class: Opioid agonist Therapeutic class: ) CII CII Confederation of Indian Industry CII Chartered Insurance Institute (UK) CII Construction Industry Institute (University of Texas) CII Council of Institutional Investors for the management of severe chronic pain, and NicoDerm CQ (nicotine transdermal system nicotine transdermal system Clear Nicoderm CQ, Habitrol, Nicoderm CQ, Nicotrol, NiQuitin (UK) Pharmacologic class: Cholinergic Therapeutic class: Smoking deterrent Pregnancy risk category C ) for smoking cessation. Sales of ALZA-developed products marketed by client companies exceeded $2.5 billion in 1996. Unlike conventional forms of drug administration -- including tablets and injections -- ALZA's therapeutic systems deliver drugs at a steady, controlled rate, or in a predetermined pre·de·ter·mine v. pre·de·ter·mined, pre·de·ter·min·ing, pre·de·ter·mines v.tr. 1. To determine, decide, or establish in advance: pattern over extended periods of time. ALZA's drug delivery systems for human application include oral osmotic osmotic, adj pertaining to osmosis. osmotic pressure, n See pressure, osmotic. osmotic emanating from or pertaining to the pressure of osmosis. tablets, transdermal patches, electrotransport systems, and human implantable systems. As part of its long-term strategic plan, ALZA is expanding its sales and marketing and product development capabilities and is focusing on four therapeutic areas: oncology/AIDS, pain management, endocrinology and urology. In 1993, ALZA formed Therapeutic Discovery Corp. (TDC TDC Top Dead Center TDC Time-to-Digital Converter TDC Tabular Data Control TDC Total Development Cost TDC Texas Department of Corrections TDC The Discovery Channel TDC Torpedo Data Computer TDC Theater Deployable Communications ) to select and develop new human pharmaceutical products combining ALZA's proprietary drug delivery systems with various drug compounds, and to commercialize such products, most likely through licensing arrangements with ALZA. ALZA currently has a number of products under development with TDC. CONTACT: ALZA Corp. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion